Skip to main content
NIH funding notice RFA-DA-24-029

Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required)

Closed on November 2, 2023.

Posted
May 16, 2023
Close date
November 2, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $495,024 in first-year total cost, median $495,024.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 BSW-N (M2)]1

Most frequent institutions

  1. UNIVERSITY OF PENNSYLVANIA1
Competing awards under RFA-DA-24-029 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Psilocybin: Capturing brain mechanisms of motivation and neurocognition in individuals with opioid use disorder1R61DA061206-01CHILDRESS, ANNA ROSEKAMPMAN, KYLE MATTHEWUNIVERSITY OF PENNSYLVANIA, PA$495,024ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-24-029: Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required) | ScienceDex | ConductScience